OptiNose, Inc. (OPTN)
| Previous close | 1.0800 |
| Open | 1.0800 |
| Bid | 1.0900 x 400 |
| Ask | 1.1200 x 600 |
| Day's range | 1.0800 - 1.1200 |
| 52-week range | 0.8000 - 2.1000 |
| Volume | |
| Avg. volume | 891,421 |
| Market cap | 125.473M |
| Beta (5Y monthly) | -0.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2700 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.50 |
ZacksProfound Medical (PROF) Surges 6.0%: Is This an Indication of Further Gains?
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
GlobeNewswireExpanded Access to XHANCE with Addition to National Commercial Formularies
YARDLEY, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that XHANCE® (fluticasone propionate) has been added to Express Scripts’ national formularies, including the National Preferred, Flex, and Basic formularies, among the largest commercial formularies in the U.S. with more than 24 million lives. “XHANCE is approved for treatment of chronic rhinosinusitis
Simply Wall St.When Will OptiNose, Inc. (NASDAQ:OPTN) Breakeven?
OptiNose, Inc. ( NASDAQ:OPTN ) is possibly approaching a major achievement in its business, so we would like to shine...
